Lumenis, a manufacturer of medical and cosmetic laser and light-based systems, has obtained the US Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare (MHLW) approvals for its Array LaserLink pattern scanning device, for multi-spot laser photocoagulation.

The new device has been designed for a variety of ophthalmic uses, including diabetic retinopathy, choroidal neovascularisation, branch retinal vein occlusion and retinal tears or detachments.

The pattern scanning device provides greater predictability in retinal treatments, while presumably less collateral damage to the retina.

The Array LaserLink, featuring shorter pulse duration and sequential multi-spot delivery, is expected to benefit both clinicians and patients as it helps save treatment time with shorter laser sessions and reduces patient discomfort.

Array LaserLink features an examination slit lamp for use as a therapeutic laser delivery device which offers a variety of features when attached to a compatible Lumenis photocoagulator.

The Array LaserLink includes a remote touchpad which helps control treatment parameters and micromanipulation and enhances the physician’s workflow and efficiency.

It allows the doctor to maintain visualisation of the patient’s retina through the slit lamp while changing treatment parameters such as spot size, spacing, number of spots in the pattern, pattern rotation and laser power.

Array LaserLink device provides physicians with a choice of laser patterns. In scanning mode, the device can deliver 532nm and 577nm wavelengths and in single spot mode it can deliver 577nm and 659nm wavelengths.

In addition, it also offers continuous variable spot size ranging from 50-1,000 micrometres.

By providing multi-spot patterns, multi-wavelength compatibility, continuous variable spot size, and variable distance between spots, the Array LaserLink device helps augment the features of compatible Lumenis lasers systems.

"We believe Array will bring important benefits both to patients, clinicians and health care providers."

Lumenis Ophthalmology strategic business unit general manager and vice-president, Kfir Azoulay, noted the introduction of the Array LaserLink device in the US and Japan demonstrates and reaffirms the company’s ongoing commitment to developing and introducing advanced ophthalmic laser products and delivery devices that grow with its customers’ needs.

"We believe Array will bring important benefits both to patients, clinicians and health care providers, and we look forward to working with the ophthalmology community to integrate our next generation technology into clinical practice.

"This milestone, along with other products in our pipeline will allow Lumenis to further enhance our leadership position in the global ophthalmic laser market in general and the retina segment in particular," Azoulay said.

Lumenis will feature the Array pattern scanning LaserLink device at the American Academy of Ophthalmology Annual Meeting, taking place 16 November through to 19 November, in New Orleans, Louisiana.